3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Sarcoma
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Breast
1
Conditions
Ovarian Neoplasms
4
Fallopian Tube Neoplasms
4
Endometrial Neoplasms
4
Breast Neoplasms
4
Uterine Cervical Neoplasms
3
Prostatic Neoplasms
3
Pancreatic Neoplasms
3
Carcinoma, Ovarian Epithelial
3
Urinary Bladder Neoplasms
2
Neoplasms
2
Neoplasm Metastasis
2
Lung Neoplasms
2
Leiomyosarcoma
2
Urethral Neoplasms
1
Ureteral Neoplasms
1
Stomach Neoplasms
1
Solid Tumor
1
Small Cell Lung Carcinoma
1
Sarcoma
1
Recurrence
1
Prostate Cancer Metastatic
1
Mesothelioma, Malignant
1
Mental Retardation, X-Linked, With Or Without Seizures, Arx-Related
1
Esophageal Neoplasms
1
Colorectal Neoplasms
1
Colonic Neoplasms
1
Carcinosarcoma
1
Carcinoma, Transitional Cell
1
Carcinoma, Non-Small-Cell Lung
1
Carcinoma, Endometrioid
1
Interventions
Fluorouracil
87
Leucovorin
78
Oxaliplatin
77
Irinotecan
76
Bevacizumab
50
Cetuximab
42
Capecitabine
42
Panitumumab
17
Folfox protocol
16
Floxuridine
11
Chemotherapy, Adjuvant
11
regorafenib
10
IFL protocol
10
Nivolumab
9
Drug Therapy
9
trifluridine tipiracil drug combination
8
Surgical Procedures, Operative
8
Neoadjuvant Therapy
8
sargramostim
7
pembrolizumab
7
XELOX
7
Specimen Handling
7
Biopsy
7
Trastuzumab
6
Radiotherapy
6
Magnetic Resonance Spectroscopy
6
HMPL-013
6
tislelizumab
5
encorafenib
5
Trifluridine
5
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Colonic Neoplasms
×
rucaparib
×
Clear all
NCT04171700
2023-10-02
LODESTAR
pharmaand GmbH
Phase 2
Terminated
83 enrolled
16 charts